| 000 | 01758 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513235914.0 | ||
| 264 | 0 | _c20010816 | |
| 008 | 200108s 0 0 eng d | ||
| 022 | _a0263-6352 | ||
| 024 | 7 |
_a10.1097/00004872-200104000-00012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJonkers, I J | |
| 245 | 0 | 0 |
_aBezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. _h[electronic resource] |
| 260 |
_bJournal of hypertension _cApr 2001 |
||
| 300 |
_a749-55 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAbsorption |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBezafibrate _xtherapeutic use |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 |
_aCyclic GMP _xblood |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aFatty Acids, Nonesterified _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 |
_aHemodynamics _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertriglyceridemia _xdrug therapy |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aInsulin _xblood |
| 650 | 0 | 4 |
_aKidney _xmetabolism |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSodium _xmetabolism |
| 650 | 0 | 4 |
_aSympathetic Nervous System _xphysiopathology |
| 700 | 1 | _ade Man, F H | |
| 700 | 1 | _avan der Laarse, A | |
| 700 | 1 | _aFrölich, M | |
| 700 | 1 | _aGevers Leuven, J A | |
| 700 | 1 | _aKamper, A M | |
| 700 | 1 | _aBlauw, G J | |
| 700 | 1 | _aSmelt, A H | |
| 773 | 0 |
_tJournal of hypertension _gvol. 19 _gno. 4 _gp. 749-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00004872-200104000-00012 _zAvailable from publisher's website |
| 999 |
_c11264689 _d11264689 |
||